eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
2/2021
vol. 27
 
Share:
Share:
more
 
 
abstract:
Original paper

Growth hormone improves short stature in children with Shwachman-Diamond syndrome

Agnieszka Bogusz-Wójcik
1
,
Honorata Kołodziejczyk
2
,
Elżbieta Moszczyńska
1
,
Maja Klaudel-Dreszler
3
,
Grzegorz Oracz
3
,
Joanna Pawłowska
3
,
Mieczysław Szalecki
1, 4

1.
Department of Endocrinology and Diabetology, The Children’s Memorial Health Institute, Warsaw, Poland
2.
Anthropology Department, The Children’s Memorial Health Institute, Warsaw, Poland
3.
Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
4.
Department of Medical Sciences, Collegium Medicum, Poland
Pediatr Endocrinol Diabetes Metab 2021; 27 (2): 87–92
Online publish date: 2021/04/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Shwachman-Diamond syndrome (SDS) is a rare, autosomal recessive multisystemic disorder characterized by pancreatic insufficiency and bone marrow failure. Short stature is a recognized feature of SDS syndrome; however, systemic data concerning recombinant human growth hormone (rGH) treatment are limited. Aim of the study: To assess the effect of rGH treatment in patients with SDS.

Material and methods
Retrospective data were collected from patients with SDS and growth hormone deficiency (GHD) treated with rGH in the Children’s Memorial Health Institute in Warsaw. The annual growth velocity (GV) and height standard deviation score (SD) were compared for up to 2 years of rGH treatment.

Results
Six SDS patients (M : F = 1 : 5) treated with rGH were identified. The median age of starting rGH therapy was 7.5 years, with a mean baseline height SD of –4.06 (range: –6.3 to –2.3 SD). The height SD significantly improved to –3.3 (p = 0.002) and then –3.03 (p = 0.002), following 1 and 2 years of treatment, respectively. The average GV for the patients prior to starting treatment was 4.9 cm/year (range: 3.1–6.5 cm/year), which significantly improved to 7.6 cm/year (range: 5.7–9.6 cm/year) after 1 year of rGH treatment (p = 0.020) and to 6.7 cm/year at the end of 2 years.

Conclusions
Our study has shown that rGH treatment significantly improves the height SDS and GV of patients with SDS and GHD without any side effects. Further research is required to analyse the long-term effect of rGH therapy in patients with SDS.

keywords:

growth hormone, short stature, Shwachman-Diamond syndrome

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe